You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

fine line chemotherapy

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Colorectal Cancer Trial in Hangzhou (Fruquintinib Combined With Chemotherapy)

Not yet recruiting
  • Advanced Colorectal Cancer
  • Fruquintinib Combined With Chemotherapy
  • Hangzhou, Zhejing, China
    Zhejiang Cancer Institute & Hospital
Jun 29, 2023

Tislelizumab Combined With Chemotherapy in First-line Treatment

Active, not recruiting
  • Tislelizumab
  • +3 more
  • Beijing, China
    Cancer Institute and Hospital, Chinese Academy of Medical Scienc
Sep 6, 2023

Gastrointestinal Neuroendocrine Carcinoma Trial in Beijing (Durvalumab and Chemotherapy(oxaliplatin and capecitabine))

Recruiting
  • Gastrointestinal Neuroendocrine Carcinoma
  • Durvalumab and Chemotherapy(oxaliplatin and capecitabine)
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Oct 1, 2023

Gastric Cancer Trial (Tislelizumab, 5Fu, Paclitaxel injection)

Not yet recruiting
  • Gastric Cancer
  • (no location specified)
Feb 21, 2023

Advanced Mucosal Melanoma Trial (Envafolimab combined with recombinant human endostatin and first-line chemo)

Not yet recruiting
  • Advanced Mucosal Melanoma
  • Envafolimab combined with recombinant human endostatin and first-line chemotherapy
  • (no location specified)
Sep 15, 2023

Cancer Of Pancreas Trial (Analyze of GemCore status)

Not yet recruiting
  • Cancer Of Pancreas
  • Analyze of GemCore status
  • (no location specified)
Sep 19, 2023

Biliary Tract Tumors, Immunotherapy Trial in Beijing (Durvalumab, Lenvatinib Oral Product, Chemotherapy)

Recruiting
  • Biliary Tract Neoplasms
  • Immunotherapy
  • Beijing, Beijing, China
    Chinese Academy of Medical Sciences & Peking Union Medical Colle
Jul 6, 2023

ASCT Versus Chemotherapy as First-Line Consolidation Therapy

Completed
  • T-cell Lymphoma Adults
  • consolidation with ASCT
  • (no location specified)
Nov 25, 2023

NSCLC Trial (Ivonescimab Injection, Pembrolizumab Injection)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Ivonescimab Injection
  • Pembrolizumab Injection
  • (no location specified)
Jun 9, 2023

HR Positive HER2 Negative Advanced Breast Cancer Trial in Tianjin (Chidamide)

Recruiting
  • HR Positive HER2 Negative Advanced Breast Cancer
  • Tianjin, China
    天津市肿瘤医院
May 26, 2023

Breast Cancer Trial in Chengdu (Dalpiciclib combined with Letrozole)

Not yet recruiting
  • Breast Cancer
  • Dalpiciclib combined with Letrozole
  • Chengdu, Sichuan, China
    West China Hospital, Sichuan University
Aug 3, 2023

Nasopharyngeal Carcinoma Trial in Guangzhou (BL-B01D1, capecitabine, gemcitabine)

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Oct 31, 2023

First-Line Serplulimab Plus Chemotherapy in Treatment of

Not yet recruiting
  • Lung Cancer
  • Serplulimab plus chemotherapy
  • (no location specified)
May 16, 2023

Hepatocellular Carcinoma Trial in Hangzhou (PM8002, FOLFOX regimen)

Recruiting
  • Hepatocellular Carcinoma
  • PM8002
  • FOLFOX regimen
  • Hangzhou, Zhejiang, China
    Cancer Hospital of The University of Chinese Academy of Sciences
May 19, 2023

Pancreatic Tumors Trial (Tislelizumab)

Not yet recruiting
  • Pancreatic Neoplasms
  • (no location specified)
Dec 26, 2022

High-risk Stage II Colorectal Cancer, Stage III Colorectal Cancer, Circulating Tumor DNA Methylation Trial in Shanghai

Recruiting
  • High-risk Stage II Colorectal Cancer
  • +2 more
  • mFOLFIRINOX adjuvant chemotherapy
  • mFOLFOX6/XELOX adjuvant chemotherapy
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Jul 12, 2023

Lazertinib as the 2nd-Line Treatment in EGFR Mutation+ NSCLC

Completed
  • Non-small Cell Lung Cancer
  • (no location specified)
May 8, 2023

Pleural Mesothelioma Trial in Guangzhou (Cadonilimab+Bevacizumab+Pemetrexed+Carboplatin)

Not yet recruiting
  • Pleural Mesothelioma
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Jul 3, 2023

NSCLC Stage II, Bevacizumab, Immunotherapy Trial in Guangzhou (Serplulimab combined with bevacizumab and first-line chemo)

Not yet recruiting
  • Non-small Cell Lung Cancer Stage II
  • +3 more
  • Serplulimab combined with bevacizumab and first-line chemotherapy
  • Guangzhou, Guangdong, China
    Likun Chen
Apr 10, 2023

Pancreatic Cancer, Ultrasonography, First-line Chemo Trial in Beijing (Contrast-enhanced ultrasound(CEUS))

Recruiting
  • Pancreatic Cancer
  • +2 more
  • Contrast-enhanced ultrasound(CEUS)
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Feb 6, 2023

MPM Trial in Changchun (PM8002, Pemetrexed, Cisplatin)

Recruiting
  • MPM
  • Changchun, China
    Jilin Provincial Tumor Hospital
Jun 25, 2023

Metastatic Pancreatic Cancer Trial (FOLFIRINOX treatment)

Not yet recruiting
  • Metastatic Pancreatic Cancer
  • FOLFIRINOX treatment
  • (no location specified)
Aug 9, 2023

Solid Tumor Trial in Beijing (QLS31905, Nab paclitaxel, Gemcitabine)

Not yet recruiting
  • Solid Tumor
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Sep 10, 2023

Esophageal Cancer by AJCC V8 Stage Trial in Zhengzhou (Camrelizumab+Apatinib+Chemotherapy?Camrelizumab+Apatinib,

Recruiting
  • Esophageal Cancer by AJCC V8 Stage
  • Zhengzhou, Henan, China
    The First Affiliated Hospital of Zhengzhou University
Feb 12, 2023

Malignant Pleural Mesothelioma Trial in Cairo (Gemcitabine, supportive care)

Not yet recruiting
  • Malignant Pleural Mesothelioma
  • Cairo, Egypt
    Ain Shams University Hospital
Dec 20, 2022